Chen J, Sanberg P R, Li Y, Wang L, Lu M, Willing A E, Sanchez-Ramos J, Chopp M
Departments of Neurology, Henry Ford Health Sciences Center, Detroit, Michigan, USA.
Stroke. 2001 Nov;32(11):2682-8. doi: 10.1161/hs1101.098367.
Human umbilical cord blood cells (HUCBC) are rich in stem and progenitor cells. In this study we tested whether intravenously infused HUCBC enter brain, survive, differentiate, and improve neurological functional recovery after stroke in rats. In addition, we tested whether ischemic brain tissue extract selectively induces chemotaxis of HUCBC in vitro.
Adult male Wistar rats were subjected to transient (2-hour) middle cerebral artery occlusion (MCAO). Experimental groups were as follows: group 1, MCAO alone (n=5); group 2, 3x10(6) HUCBC injected into tail vein at 24 hours after MCAO (n=6) (animals of groups 1 and 2 were killed at 14 days after MCAO); group 3, MCAO alone (n=5); group 4, MCAO injected with PBS at 1 day after stroke (n=8); and group 5, 3x10(6) HUCBC injected into tail vein at 7 days after MCAO (n=5). Rats of groups 3, 4, and 5 were killed at 35 days after MCAO. Behavioral tests (rotarod and Modified Neurological Severity Score [mNSS]) were performed. Immunohistochemical staining was used to identify cells derived from HUCBC. Chemotactic activity of ischemia brain tissue extracts toward HUCBC at different time points was evaluated in vitro.
Treatment at 24 hours after MCAO with HUCBC significantly improved functional recovery, as evidenced by the rotarod test and mNSS (P<0.05). Treatment at 7 days after MCAO with HUCBC significantly improved function only on the mNSS (P<0.05). Some HUCBC were reactive for the astrocyte marker glial fibrillary acidic protein and the neuronal markers NeuN and microtubule-associated protein 2. In vitro, significant HUCBC migration activity was present at 24 hours after MCAO (P<0.01) compared with normal brain tissue.
Intravenously administered HUCBC enter brain, survive, migrate, and improve functional recovery after stroke. HUCBC transplantation may provide a cell source to treat stroke.
人脐带血细胞(HUCBC)富含干细胞和祖细胞。在本研究中,我们测试了静脉注射的HUCBC是否能进入大鼠脑内、存活、分化并改善中风后的神经功能恢复。此外,我们还测试了缺血脑组织提取物在体外是否能选择性诱导HUCBC的趋化性。
成年雄性Wistar大鼠接受短暂(2小时)大脑中动脉闭塞(MCAO)。实验组如下:第1组,单纯MCAO(n = 5);第2组,MCAO后24小时经尾静脉注射3×10⁶个HUCBC(n = 6)(第1组和第2组动物在MCAO后14天处死);第3组,单纯MCAO(n = 5);第4组,中风后1天经MCAO注射PBS(n = 8);第5组,MCAO后7天经尾静脉注射3×10⁶个HUCBC(n = 5)。第3、4和5组大鼠在MCAO后35天处死。进行行为测试(转棒试验和改良神经功能缺损评分[mNSS])。采用免疫组织化学染色鉴定源自HUCBC的细胞。在体外评估不同时间点缺血脑组织提取物对HUCBC的趋化活性。
MCAO后24小时用HUCBC治疗显著改善了功能恢复,转棒试验和mNSS证明了这一点(P < 0.05)。MCAO后7天用HUCBC治疗仅在mNSS上显著改善了功能(P < 0.05)。一些HUCBC对星形胶质细胞标志物胶质纤维酸性蛋白以及神经元标志物NeuN和微管相关蛋白2呈阳性反应。在体外,与正常脑组织相比,MCAO后24小时存在显著的HUCBC迁移活性(P < 0.01)。
静脉注射的HUCBC可进入脑内、存活、迁移并改善中风后的功能恢复。HUCBC移植可能为治疗中风提供一种细胞来源。